重新审视T细胞粘附分子作为癌症免疫治疗的潜在标:CD226和CD2
Yunju Jo1, Hye-In Sim1, Bohwan Yun2
1Chemical and Biological Integrative Research Center, Biomedical Research Institute, Korea Institute of Science and Technology (KIST), Seoul, South Korea.
在探索新的癌症免疫疗法点时,本文重点介绍了CD2和CD226共刺激受体. 激活这些分子可能会克服抵抗力并增强对癌症的免疫反应.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 癌症免疫疗法,包括免疫检查点抑制剂 (ICI),已经推进了癌症治疗,但在实现持久反应方面面临挑战.
- 抗癌免疫依赖于瘤微环境中的共抑制和共刺激信号的平衡.
- 造价刺激受体代表了克服当前免疫治疗局限性的有希望的目标.
研究的目的:
- 审查CD2和CD226共刺激受体的功能.
- 评估它们作为癌症免疫治疗的新型激素标的潜力.
- 探索克服对现有癌症疗法耐药性的策略.
主要方法:
- 关于CD2,CD226和癌症免疫治疗的科学出版物的文献综述.
- 对T细胞和NK细胞功能中辅助刺激途径的作用的分析.
- 检查 ICI 和 CAR T 细胞疗法的耐药性背后的机制.
主要成果:
- CD2和CD226是关键的辅助刺激分子,主要表达在T和NK细胞上,对细胞粘附和识别至关重要.
- 这些受体通过克服T细胞疲劳来增强抗瘤免疫力.
- CD2CD58轴和CD226信号传递对于改善对ICI和CAR T细胞疗法的反应至关重要.
结论:
- CD2和CD226作为新型激动性免疫疗法的标具有显著的前景.
- 针对这些辅助刺激途径可以提高现有癌症治疗的疗效.
- 对CD2和CD226激动剂的进一步研究可能会导致克服癌症免疫疗法耐药性的突破.
更多相关视频
09:53Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens
Published on: February 6, 2017
08:46A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
相关概念视频
Tumor Immunotherapy
T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...
Immunoglobulin-like Cell Adhesion Molecules
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...
Cell Adhesion Molecules - Types and Functions
CAM Families
The Integrin family of proteins is primarily involved...
Selectins
Targeted Cancer Therapies
There are several types of targeted therapies against...
